HRHailey S. Ross

Hailey S. Ross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hailey S. Ross has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Somatic mtDNA mutation burden shapes metabolic plasticity in leukemogenesis

    by Xiujie Li-Harms, Jingjun Lu, Yu Fukuda, John Lynch, Aditya Sheth, Gautam Pareek, Marcin M. Kaminski, Hailey S. Ross, Christopher W. Wright, Amber L. Smith, et al.

    The role of somatic mitochondrial DNA (mtDNA) mutations in leukemogenesis remains poorly characterized. To determine the impact of somatic mtDNA mutations on this process, we assessed the leukemogenic potential of hematopoietic progenitor cells (HPCs) from mtDNA mutator mice (Polg D257A) with or without NMyc overexpression. We observed a higher incidence of spontaneous leukemogenesis in recipients transplanted with heterozygous Polg HPCs and a lower incidence of NMyc-driven leukemia in those with homozygous Polg HPCs compared to controls. Although mtDNA mutations in heterozygous and homozygous HPCs caused similar baseline impairments in mitochondrial function, only heterozygous HPCs responded to and supported altered metabolic demands associated with NMyc overexpression. Homozygous HPCs showed altered glucose utilization with pyruvate dehydrogenase inhibition due to increased phosphorylation, exacerbated by NMyc overexpression. The impaired growth of NMyc-expressing homozygous HPCs was partially rescued by inhibiting pyruvate dehydrogenase kinase, highlighting a relationship between mtDNA mutation burden and metabolic plasticity in leukemogenesis.


  • Open Access

    Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts

    by Hailey S. Ross, Ronald Dallas, Jose Ferrolino, Madeline Burton, Kim Allison, Shane Cross, Randall Hayden, Asuncion Mejias, Diego Hijano

    Not-yet-known not-yet-known not-yet-known unknown Background: Pediatric immunocompromised patients are at an increased risk of severe respiratory syncytial virus (RSV) infection. Here, we aimed to describe the clinical course and outcomes of RSV infection in immunocompromised children. Methods: This single-center study was conducted at St. Jude Children’s Research Hospital in immunocompromised children ≤21 years old, who had a positive RSV clinical test in the clinic or hospital from 2007 to 2019. Demographic and clinical characteristics, laboratory values, delays in the treatment of patients’ underlying conditions, and outcomes were extracted from the patients’ electronic medical records. Multivariate models were constructed to identify risk factors predictive of severe RSV LRTI. Results: In total, 391 patients were included. Most children (86%) were > 2 years of age, with a median age of 5 years. Acute lymphoblastic leukemia (ALL) was the most common underlying disease. Most patients presented with upper respiratory tract infections (n = 335; 85.7%). Approximately 6% of patients progressed to lower respiratory tract infections. More than half (58.8%) of the patients were hospitalized, and therapy for the underlying disease was modified or delayed due to RSV infection in one-third of the patients. Severe RSV infections were observed in 62 patients (15.9%). All-cause mortality was reported in 10 patients (2.6%), with three RSV-related deaths (0.7%). Conclusions: A high proportion of immunocompromised children with RSV infection require hospitalization. Hospitalization was observed in those aged >2 years, and an overall treatment delay for the underlying disease occurred in one-third of the patients. The burden associated with RSV in immunocompromised children is high irrespective of age and has direct and indirect consequences on their cancer treatment plans.

  • Open Access

    RSV Infection and Preliminary Immunodeficiency Scoring Index (ISI) Results Among Pediatric Hematopoietic Cell Recipients (HCT) and Solid Organ Transplant Recipients (SOT): A Multi-Site U.S. Study

    by Hailey S Ross, Ronald H Dallas, Sapna A Pardasani, Jose A Ferrolino, Madeline C Burton, Gabriela M Maron, Lara A Danziger-Isakov, Janet A Englund, Chikara Ogimi, Diego R Hijano

    Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infections (LRTI) in children, with poorer outcomes more likely in immunocompromised hosts. The Immunodeficiency Scoring Index (ISI) to stratify the risk of severe disease has been developed and applied in adults undergoing transplantation with RSV infections. However, such scores are not available for children undergoing transplantation. Using a retrospective multi-site study, we developed an ISI score index for predicting RSV disease progression in pediatric transplant recipients. Pediatric (< 18 years old at transplant) HCT and SOT recipients at 22 U.S. transplant centers who underwent transplant (2010-2019) and had RSV detected within 365 days of conditioning or transplant were included. De-identified data were entered by the participating sites in the REDCap database. The ISI score criteria are listed in Table 1. The cases were summarized using the ISI score. Progression to LRTI and death related to RSV were summarized using the ISI score. Fisher’s exact and non-parametric tests were used to compare ISI risk categories with the outcomes of interest (progression to LRTI and RSV-related mortality). In total, 352 patients were included in this analysis (220 HCT and 132 SOT). The majority were male (55%) and Caucasian/white (58.2%), with a median age of 4 years (range, 0 – 17 years). In total, 27 cases progressed to LRTI, and three deaths were related to RSV. The median ISI score was 1 (range: 0–10). The cases were categorized into low (245, 69.6%), moderate (81, 23%), or high (26, 7.4%) ISI risk categories (Table 1). The ISI score categories did not significantly predict progression to LRTI- or RSV-related deaths. RSV is associated with poor outcomes in immunocompromised pediatric patients. Development of immunodeficiency scoring index criteria could prove helpful in categorizing the risk for pediatric patients. Additional work is needed to develop a scoring system that effectively predicts pediatric immunocompromised patients at the greatest risk of RSV-related morbidity and mortality. Further investigation of our data from this large multi-site study is needed to assess all potential risk factors and scoring criteria definitions. Table 1. Immunodeficiency Scoring Index ANC: absolute neutrophil count; ALC: absolute lymphocyte count; GVHD: graft versus host disease Table 1. Immunodeficiency Scoring Index ANC: absolute neutrophil count; ALC: absolute lymphocyte count; GVHD: graft versus host disease